Publicacions en què col·labora amb Óscar Fernández Fernández (54)

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2019

  1. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  2. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2017

  1. Metabolomic signatures associated with disease severity in multiple sclerosis

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, Núm. 2

  2. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  3. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  2. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8

  3. Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score

    Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150

  4. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627

  2. A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1104-1111

  3. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  4. Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

    Neurologia, Vol. 30, Núm. 5, pp. 302-314

  5. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e147

  6. Genome-wide significant association with seven novel multiple sclerosis risk loci

    Journal of Medical Genetics, Vol. 52, Núm. 12, pp. 848-855

  7. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology, Vol. 77, Núm. 3, pp. 447-457

  8. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  9. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

2014

  1. Biomarkers in multiple sclerosis: An update for 2014

    Revista de Neurologia, Vol. 58, Núm. 12, pp. 553-570